Drugs / M-M-R II
M-M-R II
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07539155 | Jun 2026 → Aug 2028 expected | malignant pancreatic neoplasm | University of Arkansas | Recruiting | No outcome recorded |
| Phase 1/2 | NCT00258726 | Oct 2005 → Jul 2007 | chickenpox, measles, mumps infectious disease, rubella | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01049035 | Dec 2009 → Feb 2012 | meningitis, meningococcal infection | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 34 trials · 1 missed | ||||||
| Phase 3 | NCT04333732 | Sep 2020 → Aug 2021 | COVID-19 | Washington University School of Medicine | Completed | Missed primary |
| Phase 3 | NCT03893448 | Jun 2019 → May 2021 | pneumococcal infection | Merck Sharp & Dohme LLC | Completed | Mixed |
| Phase 3 | NCT00432523 | Jan → Sep 2005 | chickenpox, measles, mumps infectious disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00197015 | Oct 2003 → Jun 2009 | hepatitis A virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT00432731 | Dec 2004 → Sep 2005 | chickenpox, measles, mumps infectious disease, rubella | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Comparator or background therapy24 trials | ||||||
| Phase 2 | NCT00861744 Comparator | Jun 2009 → Jul 2010 | measles, mumps infectious disease, rubella | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00134719 Background | Apr 2005 → Jul 2006 | haemophilus infectious disease, meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00986232 Comparator | Apr 1999 → Apr 2000 | chickenpox, measles, mumps infectious disease, rubella | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT06824194 Background | Feb 2025 → Oct 2027 expected | — | Sanofi | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06736041 Background | Dec 2024 → May 2027 expected | — | Sanofi Pasteur, a Sanofi Company | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04016714 Background | Aug 2019 → Oct 2021 | pneumococcal infection | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 3 | NCT03620162 Background | Oct 2018 → Dec 2020 | pneumococcal infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT03621670 Background | Jul 2018 → Dec 2024 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT03239873 Background | Oct 2017 → Aug 2018 | chickenpox | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT02058563 Comparator | Jul 2014 → May 2015 | measles, mumps infectious disease, rubella | GlaxoSmithKline | Completed | Met primary |
| Phase 3 | NCT01626794 Background | Jul 2014 → Oct 2015 | chickenpox | Merck Sharp & Dohme LLC | Withdrawn | No outcome recorded |
| Phase 3 | NCT02062502 Background | Mar 2014 → Feb 2015 | chickenpox | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 3 | NCT01702428 Comparator | Nov 2012 → Nov 2014 | measles, mumps infectious disease, rubella | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01681992 Comparator | Oct 2012 → Feb 2015 | measles, mumps infectious disease, rubella | GlaxoSmithKline | Completed | Mixed |
| Phase 3 | NCT01621802 Comparator | Jun 2012 → Jul 2015 | viral infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01346293 Background | Apr 2011 → May 2013 | diphtheria, measles, pertussis, poliomyelitis +1 | Sanofi Pasteur, a Sanofi Company | Completed | Met primary |
| Phase 3 | NCT00839917 Comparator | Feb → May 2008 | chickenpox, measles, mumps infectious disease, rubella | Merck Sharp & Dohme LLC | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00345683 Background | Jul 2007 → Sep 2008 | haemophilus infectious disease, meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00289783 Background | Feb 2006 → Aug 2007 | haemophilus infectious disease, meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00148941 Background | Jan 2005 → Nov 2006 | diphtheria, tetanus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00985166 Comparator | Aug 2000 → May 2002 | measles, mumps infectious disease, rubella, varicella zoster infection | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 3 | NCT00984295 Comparator | Jun 2000 → Oct 2001 | chickenpox, measles, mumps infectious disease, rubella | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00985153 Comparator | Mar 2000 → May 2001 | chickenpox, measles, mumps infectious disease, rubella | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00975507 Comparator | Mar 1998 → Jan 1999 | measles, mumps infectious disease, rubella, varicella zoster infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-03-06 | Merck Sharp & Dohme LLC | Regulatory US FDA Approves Intramuscular Administration for Merck’s MMRV Family of Vaccines: M-M-RII (Measles, Mumps, and Rubella Virus Vaccine Live), VARIVAX (Varicella Virus Vaccine Live), and ProQuad (Measles, Mumps, Rubella and Varicella Virus Vaccine Live) merck.com ↗
In the U.S., the only measles, mumps, rubella, and varicella vaccines that can be administered IM are M-M-R ® II , VARIVAX ® , and ProQuad ® . |
All press releases naming this drug 1 release
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 35 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | M-M-RII | “All participants will be randomized to receive either one dose each of DTap-IPV + Measles, Mumps, and Rubella Virus Vaccine Live (M-M-R®II) + VARIVAX® or one dose each of...” NCT01346293 ↗35“Five hundred seven healthy children aged 12 to 15 months received subcutaneous injections of VARIVAX on day 0 and the measles, mumps and rubella vaccine (M-M-R II) on day 42 or...” PMID 19305145 ↗ Jul 2009 “GSK Biologicals' Inactivated Hepatitis A Vaccine (Havrix™) Co-administered With Merck & Company, Inc. Measles-Mumps-Rubella Vaccine (M-M-RII) & Merck & Co Varicella Vaccine...” NCT00197015 ↗ “an injection of the measles, mumps, rubella (MMR) vaccine developed by Merck \& Co. (Merck's M-M-R® II) into the tumor is safe and effective in making the tumor smaller.” NCT07539155 ↗ “2 doses of VARNSP given concomitantly with M-M-R™ II, ∼3 months apart” PMID 29087781 ↗ Dec 2017 “MMR II vaccine (control; M-M-R II, Merck&Co Inc.)” PMID 29902133 ↗ Jul 2018 “measles, mumps, and rubella vaccine (M-M-R™ II)” PMID 32429738 ↗ May 2020 “M-M-R II; Merck, USA” PMID 28481690 ↗ May 2017 |
| Known as | M-M-R Vax Pro | “Subjects received one dose of the licensed vaccine M-M-R II (also known as M-M-R Vax Pro) Lot 1 or Lot 2 along with Kinrix and ProQuad vaccines at Visit 1 (Day 0).” NCT01621802 ↗ |
| Known as | MMR | “M-M-R II (MMR) was administered intramuscularly on Day 301.” NCT03621670 ↗ |
| Known as | MMR vaccine | “an injection of the measles, mumps, rubella (MMR) vaccine developed by Merck \& Co. (Merck's M-M-R® II) into the tumor is safe and effective in making the tumor smaller.” NCT07539155 ↗ |
| Modality | Vaccine | “M-M-R II vaccine” NCT00148941 ↗ |
| Route | Subcutaneous | “1 dose administered subcutaneously” NCT00197015 ↗ |